Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Lung Cancer. 2021 Oct 8;162:23–28. doi: 10.1016/j.lungcan.2021.10.001

Table 2.

Treatment-Related Adverse Events Reported in ≥10% of All Subjects

Adverse Event Combination Treatment (SNX-5422 + Carboplatin/Paclitaxel)
All (N=23)
Any Grade n (%) Grade 3/4 n (%)
Any 22 (96) 11 (48)
Diarrhea 16 (70) 6 (26)
Nausea 11 (48) 2 (9)
Fatigue 9 (39) 0
Alopecia 6 (26) 0
Vomiting 6 (26) 1 (4)
Thrombocytopenia 4 (17) 0
Neutropenia 3 (13) 2 (9)
ALT increased 3 (13) 1 (4)
ALP increased 3 (13) 0
Neuropathy* 4 (17) 1 (4)
SNX-5422 Maintenance Monotherapy (N=13)
Grade 1 n (%) Grade 2 n (%) Grade 3 n (%) Grade 4 n (%) All Grade n (%)
Any 1 (8) 4 (31) 2 (15) 0 7 (54)
Diarrhea 0 1 (8) 2 (15) 0 3 (23)
Nausea 2 (15) 0 0 0 2 (15)
Fatigue 1 (8) 1 (8) 0 0 2 (15)
Decreased appetite 1 (8) 1 (8) 0 0 2 (15)
*

includes peripheral neuropathy and peripheral sensory neuropathy; one patient with adenocarcinoma was treated with SNX-5422 and included in the safety population, but was later found to not meet eligibility criteria and was withdrawn.